Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug phase 3 maintenance study in moderately to severely active ulcerative colitis
jRCT2031250580Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of duvakitug in autoimmune colitis (4 arms), sponsored by Sanofi. Primary endpoint: Clinical remission by modified Mayo Score in Pivotal Maintenance Sub-Study Cohort 1. Started Apr 2026; status: recruiting.
02
Drugs
duvakitug
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031250580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250580.